12 December 2024
Therapeutic Trials in Alzheimer’s Disease: Where Are We Now?
Alzheimer’s disease (AD), the most common form of dementia among older adults, remains a major scientific and clinical challenge, particularly regarding its early diagnosis and treatment. Decades of significant efforts have been made to find the cause(s), pathogenic mechanisms, biomarkers for early detection, and treatment of AD. A new collection of papers released simultaneously in the Journal of Alzheimer’s Disease and its companion book series Advances in Alzheimer’s Disease provides an in-depth overview and assessment of the state of the art of treatments and their varying degrees of success and the research behind them.
10 December 2024
Journal of Alzheimer’s Disease publishes key UNTHSC study on biomarkers in diverse populations
A team from the University of North Texas Health Science Center at Fort Worth has had a key study published in the Journal of Alzheimer’s Disease. Lubnaa Abdullah, Psy.D., ABPP, Assistant Professor within the Department of Family and Osteopathic Manipulative Medicine at the Texas College of Osteopathic Medicine and Fan Zhang, PhD, James Hall, PhD, and Sid O’Bryant, PhD. conducted the largest characterization of plasma neurofilament light chain (NfL) in community-dwelling non-Hispanic Blacks.
22 November 2024
New Study Highlights Physician Perspectives on Emerging Anti-Amyloid Treatments for Alzheimer’s Disease in Israel
In a recent study, Tel Aviv Sourasky Medical Center has shed light on physician attitudes toward novel anti-amyloid treatments (ATT) for Alzheimer’s disease (AD), revealing a spectrum of opinions across key specialties. With Israel’s health system structured to provide universal healthcare, the high out-of-pocket costs for new AD therapies have raised questions among medical professionals about the feasibility and practicality of implementing these treatments.
9 October 2024
Thirty Years of Alzheimer's Disease Research: Preventive Strategies Hold Promise for Risk Reduction While Cure Remains Elusive
A supplement celebrating the 100th volume of the Journal of Alzheimer’s Disease provides a unique and insightful overview of the state of the art in the field
12 September 2024
Research Spotlight: Implementation of a Lifestyle Dementia Prevention Intervention
This intervention is a virtual, group-based program for older patients (age 60+) with subjective cognitive decline who are at risk for AD/ADRD. Group members learn mindfulness and behavioral strategies to set goals to improve physical activity, sleep, nutrition, and other lifestyle factors linked to lower rates of AD/ADRD. The goal of our study was to qualitatively identify the challenges and supportive factors impacting the acceptability, appropriateness and feasibility of this intervention within the healthcare setting based on focus groups with healthcare professionals.
11 September 2024
Journal of Alzheimer's Disease's Outreach Initiatives Aim to Amplify Underrepresented Voices from Africa and South America
As part of its commitment to represent researchers from all parts of the world, the Journal of Alzheimer's Disease (JAD) is pleased to announce active outreach initiatives to amplify the voices of underrepresented researchers from Afric
29 August 2024
2024 JAD Editorial Board Update
To keep our JAD editors, authors, and readers informed of JAD's progress and development, the journal hereby shares the 2024 editorial update, which includes highlights such as the best-viewed papers of 2023, the most popular press releases, and journal statistics such as the turnaround times and submission rates.
14 August 2024
Possible explanation for link between diabetes and Alzheimer's
People with type 2 diabetes are at increased risk of Alzheimer's disease and other adverse cognitive health issues. A new study conducted at by Umeå University, Sweden, shows that the reason for the correlation may be that people with type 2 diabetes have more difficulty getting rid of a protein that potentially increases the likelihood of contracting the disease.
9 July 2024
Robert A. Rissman, PhD, Receives the 2024 Alzheimer Award
The Journal of Alzheimer’s Disease (JAD) is pleased to announce that Robert A. Rissman, PhD, University of Southern California, is the recipient of the 2024 Alzheimer Award. He is lead author of the groundbreaking article “Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer’s Disease.” The award is proudly sponsored by JAD’s publisher IOS Press, now part of Sage.
6 July 2024
Groundbreaking Ecosystem Map Reveals Innovative Collaborations, Care Pathways, and Technologies for Dementia
A new Journal of Alzheimer's Disease article unveils an innovative tool demonstrating how key sectors and technologies can positively impact people living with dementia. The article provides a visual summary of dementia best practices from around the world in one compact tool for everyone in the dementia ecosystem—including people living with dementia; their family, friends, and communities; policymakers, employers, health system leaders, clinicians, social services providers, educators; researchers, technology entrepreneurs, and investors.
Pages
